GlassScriptPhysician profile
Charlene Warner Oldfield
NPI 1639598055
$6,963.62
in general payments reported to CMS, 2019-2025
26 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.00 · 2022: $331 · 2023: $2,032 · 2024: $2,403 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,413 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,413.01 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,986.57 | 2022-2025 | |
| Janssen Biotech, INC. | $710.73 | 2022-2025 | Tremfya |
| Amgen INC. | $698.11 | 2022-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $508.87 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $381.52 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $369.38 | 2023-2025 | Zoryve |
| Genzyme Corporation | $363.67 | 2022-2025 | |
| Leo Pharma INC. | $302.55 | 2022-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $298.03 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $260.90 | 2023-2025 | Winlevi, Absorica Ld, Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.22 | 2023 | Spevigo, Cyltezo |
| Pfizer INC. | $161.69 | 2022-2025 | |
| Dermavant Sciences, INC. | $128.75 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $127.17 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $126.60 | 2022-2024 | Taltz |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $69.45 | 2024-2025 | Opzelura |
| Kyowa Kirin, INC. | $42.25 | 2023-2024 | Poteligeo |
| Verrica Pharmaceuticals INC. | $39.06 | 2023 | Ycanth |
| Biofrontera INC. | $38.47 | 2024-2025 | Ameluz, Rhodoled Xl, Xepi |
| Helsinn Therapeutics (U.S.), INC. | $35.52 | 2023-2025 | Valchlor |
| Mylan Institutional INC. | $34.98 | 2023 | Hulio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Springworks Therapeutics, INC. | $27.96 | 2025 | Gomekli |
| Organon LLC | $24.53 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $15.32 | 2025 | Nemluvio |
| Convatec INC. | $13.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Oldfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.